Ousia Pharma

Ousia Pharma, a privately held biotech company spun out from the University of Copenhagen, is developing innovative peptide-drug conjugates to treat obesity and metabolic diseases. The company has pioneered a first-in-class drug-targeting approach that utilizes incretin hormone analogs to deliver small-molecule neuroplasticity modulators directly to the appetite control center in the brain. This groundbreaking strategy aims to provide transformative treatments for patients with obesity and its associated cardiometabolic conditions.